×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
FATE – fate therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
FATE
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/16
09:00 am
fate
Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases Without the Need for Conditioning Chemotherapy at the AACR Annu
Low
Report
Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases Without the Need for Conditioning Chemotherapy at the AACR Annu
4/16
01:28 am
fate
Fate Therapeutics Details Off-the-Shelf CAR T Progress in Lupus and Solid Tumors at Needham Conference [Yahoo! Finance]
Medium
Report
Fate Therapeutics Details Off-the-Shelf CAR T Progress in Lupus and Solid Tumors at Needham Conference [Yahoo! Finance]
4/9
09:00 am
fate
Fate Therapeutics to Participate in Upcoming Second Quarter 2026 Conferences
Medium
Report
Fate Therapeutics to Participate in Upcoming Second Quarter 2026 Conferences
4/2
04:05 pm
fate
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
3/27
09:15 am
fate
Scalable Biotech Manufacturing Unlocks a $14B Market
Medium
Report
Scalable Biotech Manufacturing Unlocks a $14B Market
3/18
11:30 am
fate
The $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven’t Noticed
Medium
Report
The $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven’t Noticed
3/16
04:20 am
fate
Fate Therapeutics Details FT819 CAR T Manufacturing and Phase II Lupus Trial Plans at Conference [Yahoo! Finance]
Medium
Report
Fate Therapeutics Details FT819 CAR T Manufacturing and Phase II Lupus Trial Plans at Conference [Yahoo! Finance]
3/4
04:05 pm
fate
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/26
06:21 pm
fate
Form SCHEDULE 13G/A FATE THERAPEUTICS INC Filed by: VANGUARD GROUP INC
Low
Report
Form SCHEDULE 13G/A FATE THERAPEUTICS INC Filed by: VANGUARD GROUP INC
2/26
09:08 am
fate
Form 10-K FATE THERAPEUTICS INC For: Dec 31
Medium
Report
Form 10-K FATE THERAPEUTICS INC For: Dec 31
2/26
09:04 am
fate
Form 8-K FATE THERAPEUTICS INC For: Feb 26
Medium
Report
Form 8-K FATE THERAPEUTICS INC For: Feb 26
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
12/7
Fate Therapeutics Announces Clinical Data from Landmark Phase 1 Studies of First-ever Universal, Off-the-shelf, iPSC-derived NK Cell Cancer Immunotherapy Programs
41.3%
12/14 Edited Transcript of FATE earnings conference call or presentation 5-Nov-19 10:00pm GMT [Yahoo! Finance News] 10.7%
4/2 Fate Therapeutics Announces First Patient Treated in First-in-human Clinical Trial of FT596 and Provides Corporate Update 9.2%
11/6 Fate Therapeutics Inc (NASDAQ: FATE) was downgraded by analysts at Mizuho to a "buy" rating. 8.7%
2/12 Fate Therapeutics Inc (NASDAQ: FATE) had its "overweight" rating re-affirmed by analysts at Wells Fargo & Co. They now have a $34.00 price target on the stock, up previously from $24.00. 8.5%
3/3 Fate Therapeutics Inc (NASDAQ: FATE) had its price target raised by analysts at Roth Capital from to . 7.9%
4/8 Fate Therapeutics Inc (NASDAQ: FATE) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $27.00 price target on the stock. 7.8%
10/19 Have Fate Therapeutics, Inc. (NASDAQ:FATE) Insiders Been Selling Their Stock? [Yahoo! Finance News] 7.6%
4/14 Fate Therapeutics Inc (NASDAQ: FATE) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 7.4%
4/4 Growth Investors: Industry Analysts Just Upgraded Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts By 13% [Yahoo! Finance News] 7.1%
12/14 Edited Transcript of FATE earnings conference call or presentation 5-Nov-19 10:00pm GMT [Yahoo! Finance News] 10.7%
4/2 Fate Therapeutics Announces First Patient Treated in First-in-human Clinical Trial of FT596 and Provides Corporate Update 9.2%
11/6 Fate Therapeutics Inc (NASDAQ: FATE) was downgraded by analysts at Mizuho to a "buy" rating. 8.7%
2/12 Fate Therapeutics Inc (NASDAQ: FATE) had its "overweight" rating re-affirmed by analysts at Wells Fargo & Co. They now have a $34.00 price target on the stock, up previously from $24.00. 8.5%
3/3 Fate Therapeutics Inc (NASDAQ: FATE) had its price target raised by analysts at Roth Capital from to . 7.9%
4/8 Fate Therapeutics Inc (NASDAQ: FATE) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $27.00 price target on the stock. 7.8%
10/19 Have Fate Therapeutics, Inc. (NASDAQ:FATE) Insiders Been Selling Their Stock? [Yahoo! Finance News] 7.6%
4/14 Fate Therapeutics Inc (NASDAQ: FATE) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 7.4%
4/4 Growth Investors: Industry Analysts Just Upgraded Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts By 13% [Yahoo! Finance News] 7.1%
TOP News Decliners
11/6
Fate Therapeutics, Inc. (FATE) CEO Scott Wolchko on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha]
-14.7%
3/3 Fate Therapeutics, Inc. (FATE) CEO Scott Wolchko on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] -12.6%
4/3 Fate Therapeutics Inc (NASDAQ: FATE) had its "buy" rating re-affirmed by analysts at Mizuho. They now have a $40.00 price target on the stock. -11.8%
8/14 Fate Therapeutics Announces Issuance of Foundational U.S. Patent Covering iPSC-derived CAR T Cells -10.1%
3/31 Form 4 FATE THERAPEUTICS INC For: Mar 30 Filed by: RASTETTER WILLIAM H -9.0%
3/12 Fate Therapeutics Inc (NASDAQ: FATE) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. -8.3%
4/28 Fate Therapeutics Inc (NASDAQ: FATE) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -7.4%
5/30 Fate Therapeutics Inc (NASDAQ: FATE) is now covered by analysts at Guggenheim. They set a "buy" rating on the stock. -7.1%
9/30 Fate Therapeutics Inc (NASDAQ: FATE) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating on the stock. -6.8%
8/6 Form 10-Q FATE THERAPEUTICS INC For: Jun 30 -6.5%
3/3 Fate Therapeutics, Inc. (FATE) CEO Scott Wolchko on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] -12.6%
4/3 Fate Therapeutics Inc (NASDAQ: FATE) had its "buy" rating re-affirmed by analysts at Mizuho. They now have a $40.00 price target on the stock. -11.8%
8/14 Fate Therapeutics Announces Issuance of Foundational U.S. Patent Covering iPSC-derived CAR T Cells -10.1%
3/31 Form 4 FATE THERAPEUTICS INC For: Mar 30 Filed by: RASTETTER WILLIAM H -9.0%
3/12 Fate Therapeutics Inc (NASDAQ: FATE) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. -8.3%
4/28 Fate Therapeutics Inc (NASDAQ: FATE) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -7.4%
5/30 Fate Therapeutics Inc (NASDAQ: FATE) is now covered by analysts at Guggenheim. They set a "buy" rating on the stock. -7.1%
9/30 Fate Therapeutics Inc (NASDAQ: FATE) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating on the stock. -6.8%
8/6 Form 10-Q FATE THERAPEUTICS INC For: Jun 30 -6.5%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: